SPX4,228.48-55.26 -1.29%
DIA337.04-2.88 -0.85%
IXIC12,705.22-260.13 -2.01%

Medicenna's Lead Cancer Program Shows Preliminary Anti-Cancer Activity In Solid Tumor Study

Benzinga · 07/27/2022 13:42
  • Medicenna Therapeutics Corp (NASDAQ:MDNAannounced new clinical data from the Phase 1/2 ABILITY study of MDNA11.
  • The data provide preliminary evidence of MDNA11's single-agent anti-cancer activity in patients with advanced solid tumors who have been unresponsive to other treatments.
  • MDNA11 treatment in Cohort 4 (comprised of two step-up doses of 30 µg/kg followed by fixed doses of 60 µg/kg every two weeks) was not associated with any dose-limiting toxicities.
  • The Safety Review Committee has approved dose escalation for Cohort 5 to the 90 µg/kg dose every two weeks following two priming doses at 30 µg/kg.
  • Significant increases in eosinophil count from baseline were not observed with MDNA11 treatment.
  • Four of ten evaluable patients achieved tumor control, including two patients at the 10 µg/kg dose (sarcoma and metastatic melanoma), one sarcoma patient at the 30 µg/kg dose, and one pancreatic cancer patient in Cohort 4 receiving the 60 µg/kg dose.
  • The first imaging scans in the remaining four patients enrolled at the 60 µg/kg dose are expected in September.
  • Treatment with MDNA11 leads to multi-fold increases in anti-cancer immune cells without stimulation of cells that cause immunosuppression and toxicity.
  • Price Action: MDNA shares are up 12.20% at $1.56 during the market session on the last check Wednesday.